Analyses of plasma protein levels in relation to body composition in the UK Biobank

Abstract Background Excess fat mass is causally linked to multiple diseases, but the use of existing therapies, such as glucagon-like peptide-1 receptor agonists, is limited by varying effects and common side effects, including loss of fat-free mass. We aimed to identify proteins associated with fat mass, but ideally not also associated with fat-free mass, as potential drug targets for alternative therapeutic strategies. Methods We used UK Biobank data on plasma levels of 3K proteins ( n = 35K) and fat and fat-free mass ( n = 368K). We applied a machine learning procedure to select proteins for downstream cis Mendelian randomisation analyses, which estimated associations of genetically predicted protein levels with fat mass. These were followed by colocalisation analyses to assess shared causal genetic variants and further cis Mendelian randomisation analyses to assess associations with fat-free mass. Results Here we present evidence on the associations of genetically predicted levels of 21 proteins with fat mass, including five which also colocalise with the trait (AGER, CRIM1, DNER, NEFL, and PRRT3). Seven of the 21 proteins have no clear association with fat-free mass, and ADM has an association with fat-free mass opposite in direction to its association with fat mass, suggesting that modulating these proteins may be less likely to also lower fat-free mass. Two proteins, AGER and ADM, have been investigated in advanced-stage clinical trials for indications unrelated to adiposity. Conclusions These findings support prioritising several proteins for further research as potential drug targets for fat mass reduction. They highlight proteins that may help diversify therapy options beyond glucagon-like peptide-1 receptor agonists and suggest possible repurposing opportunities.

Authors

Institutions

Publication Details

Journal
Communications Medicine
Published
2026-11-13
DOI
https://doi.org/10.1038/s43856-026-01964-1
Primary Topic
Genetic Associations and Epidemiology
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Analyses of plasma protein levels in relation to body composition in the UK Biobank

Ben Lacey, Derrick Bennett, Tin Orešković, Sarah Lewington et al.
3 links
Communications Medicine
Genetic Associations and Epidemiology
article

Analyses of plasma protein levels in relation to body composition in the UK Biobank

Ben Lacey, Derrick Bennett, Tin Orešković, Sarah Lewington, Maria Sofia Massa
article en

Abstract

Abstract Background Excess fat mass is causally linked to multiple diseases, but the use of existing therapies, such as glucagon-like peptide-1 receptor agonists, is limited by varying effects and common side effects, including loss of fat-free mass. We aimed to identify proteins associated with fat mass, but ideally not also associated with fat-free mass, as potential drug targets for alternative therapeutic strategies. Methods We used UK Biobank data on plasma levels of 3K proteins ( n = 35K) and fat and fat-free mass ( n = 368K). We applied a machine learning procedure to select proteins for downstream cis Mendelian randomisation analyses, which estimated associations of genetically predicted protein levels with fat mass. These were followed by colocalisation analyses to assess shared causal genetic variants and further cis Mendelian randomisation analyses to assess associations with fat-free mass. Results Here we present evidence on the associations of genetically predicted levels of 21 proteins with fat mass, including five which also colocalise with the trait (AGER, CRIM1, DNER, NEFL, and PRRT3). Seven of the 21 proteins have no clear association with fat-free mass, and ADM has an association with fat-free mass opposite in direction to its association with fat mass, suggesting that modulating these proteins may be less likely to also lower fat-free mass. Two proteins, AGER and ADM, have been investigated in advanced-stage clinical trials for indications unrelated to adiposity. Conclusions These findings support prioritising several proteins for further research as potential drug targets for fat mass reduction. They highlight proteins that may help diversify therapy options beyond glucagon-like peptide-1 receptor agonists and suggest possible repurposing opportunities.

Communications Medicine
University of Cambridge (GB), University of Oxford (GB), UK Biobank (GB)
Health and Care Research Wales, UK Research and Innovation, Cancer Research UK, National Institute for Health and Care Research, British Heart Foundation, University of Oxford, Public Health Agency, Chief Scientist Office, Scottish Government Health and Social Care Directorate, Medical Research Council, Engineering and Physical Sciences Research Council, Economic and Social Research Council, Health and Social Care Research and Development Division, Health Data Research UK
Good health and well-being
Genetic Associations and Epidemiology
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon